Trial Profile

A Multicenter, Open-Label, Randomized Controlled Phase III Study to Compare the Efficacy and Safety/Tolerability of GFH375 Monotherapy Versus Investigator's Choice of Chemotherapy in Patients With Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VS 7375 (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Gimeracil/oteracil/tegafur; Irinotecan; Oteracil; Paclitaxel
Indications Pancreatic ductal carcinoma
Focus Registrational; Therapeutic Use
Sponsors GenFleet Therapeutics

09 Dec 2025 New trial record
04 Nov 2025 According to a Verastem Oncology Media Release, the company plans to engage with the FDA to discuss potential registration directed clinical trials in PDAC and NSCLC in 1H 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com